NEW YORK (GenomeWeb News) – Metabolon said today that it has signed an intellectual property and development agreement with the University of Michigan related to its Prostarix line of prostate cancer diagnostics.
 
Under the terms of the agreement, Metabolon has taken an exclusive license for prostate cancer aggressiveness biomarkers that were discovered in a previous collaboration between the company and the university.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.